Bako Diagnostics
Bako Diagnostics (BakoDx) is a specialized anatomic and molecular pathology laboratory providing diagnostic and therapeutic services for the skin, soft tissue, and bone of the lower extremity, serving podiatrists, dermatologists, and infectious disease specialists across the United States.
- Company typePrivate
- Founded2008
- HeadquartersAlpharetta, United States
- Headcount251–500
- GTM typeB2B
- OfferingServices
What Bako Diagnostics does
Bako Diagnostics (BakoDx) is a specialized pathology laboratory providing diagnostic and therapeutic services focused on the skin, soft tissue, and bone of the lower extremity, headquartered at 6240 Shiloh Road in Alpharetta, Georgia. Founded in 2008 and operating with 251–500 employees, the company serves podiatric physicians, dermatologists, and infectious disease specialists through a unified portfolio that includes anatomic pathology (histopathology with PAS, GMS, and Fontana-Masson stains), molecular PCR testing (notably its proprietary Onychodystrophy PCR with Terbinafine Resistance panel covering 12 resistance mutations in four reactions), microbiology with Mass Spectrometry for organism identification, ENFD (Epidermal Nerve Fiber Density) immunohistochemistry for small fiber peripheral neuropathy diagnosis, and infectious disease NAAT testing for COVID-19 and Influenza A/B. The company differentiates its reporting through an "Intelligence Reporting" methodology that pairs diagnoses with treatment recommendations, disease background, and published literature references rather than delivering raw lab data.
Bako Diagnostics firmographics
Firmographics- Name
- Bako Diagnostics
- Legal name
- Bako Diagnostics
- Website
- https://bakodx.com
- Company type
- Private
- Founded year
- 2008
- Operating status
- Acquired
- Headcount range
- 251–500 employees
- Short description
- Bako Diagnostics (BakoDx) is a specialized anatomic and molecular pathology laboratory providing diagnostic and therapeutic services for the skin, soft tissue, and bone of the lower extremity, serving podiatrists, dermatologists, and infectious disease specialists across the United States.
- Ownership category
- akta.pro rank
Bako Diagnostics industry classification
Industry- Product category
- Diagnostic Pathology Services
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Medical and Diagnostic Laboratories (62151)
- SIC
- Services-Medical Laboratories (8071)
- akta.pro primary industry
- Anatomic Pathology (Histopathology & Cytopathology) (HLAFAMAA)
- akta.pro secondary industries
- Dermatopathology (HLAKACAC), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF), Cytology & Histopathology Diagnostics (IHC, ISH, tissue-based assays) (HLAAALAI)
Keywords
Where Bako Diagnostics is headquartered
LocationHeadquarters
- HQ city
- Alpharetta
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Bako Diagnostics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Operations, Personnel, Technology or R&D, Marketing or Sales, Supply Chain
Revenue model
- Laboratory Testing Services: BakoDx provides diagnostic pathology and molecular testing services to physician offices. Services include anatomic pathology, clinical pathology, molecular PCR testing, microbiology, and specialized neurology testing. Revenue is generated through insurance billing (payor contracts) and direct patient payment for certain tests.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | COVID-19 Virus Testing - Cash Pay |
| Subscription | Monthly | Insurance-Covered Testing Services |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels6 records
Bako Diagnostics product offering
Product offeringCore offering
Bako Diagnostics is a specialty pathology laboratory providing anatomic pathology, molecular PCR testing, microbiology, and Epidermal Nerve Fiber Density (ENFD) analysis for podiatric physicians, dermatologists, and infectious disease specialists. Every test is delivered with the company's proprietary "intelligence reporting" methodology, which attaches structured treatment recommendations to the diagnostic interpretation.
Product overview
Bako Diagnostics operates as a specialized pathology laboratory focused on diagnostic and therapeutic services for the podiatric medical community, specializing in conditions affecting the skin, soft tissue, and bone of the lower extremity. The company offers a unified portfolio of diagnostic testing services centered around its core laboratory capabilities: anatomic pathology (histopathology with special stains), molecular diagnostics (PCR-based testing for onychodystrophy, skin infections, and terbinafine resistance), ENFD testing for neuropathy diagnosis, and infectious disease testing (COVID-19 and influenza). Supporting the testing services, BakoDx provides clinical therapeutic solutions (office-dispensed medications) and biopsy instruments/supplies for physician practices. The company also offers educational resources including webinars, instructional videos, and a mini-fellowship program. BakoDx was acquired by Fulgent Genetics in March 2026.
Differentiator
Problem solved
Functional benefit
Products and services
- Onychodystrophy PCR Testing with Terbinafine Resistance
- Anatomic Pathology Services
- Microbiology Testing Services
- ENFD (Epidermal Nerve Fiber Density) Testing
- BakoDx DermSTAT Skin Infection Test Suite
- Web Space Infection PCR Testing
- BakoID COVID-19 + Influenza A/B Testing
- Clinical Therapeutic Solutions (Physician-Dispensed Products)
- Biopsy Instruments & Specimen Supplies
Quantifiable outcome
- 24-hour in-house turnaround time for routine specimens
- +4 more outcomes
Companies that use Bako Diagnostics
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles3 records
Bako Diagnostics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Bako Diagnostics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Fulgent GeneticscoreFulgent Genetics completed the acquisition of Bako Diagnostics for approximately $56.9 million in cash (adjusted from initial announced price of $55.5 million). BakoDx became part of Fulgent Genetics' strategic vision to transform from a diagnostic business into a fully integrated precision medicine company. The acquisition expanded Fulgent's specialty laboratory testing capabilities into pathology services, and more than doubled its pathology sales team.
Scale indicators4 records
Recent moves6 records
Expansion highlights4 records
Bako Diagnostics competitors and assessment
Company assessmentDirect peers
- PathGroup: Large US anatomic and clinical pathology services provider serving dermatologists, podiatrists, and other specialists with a similarly distributed field-sales model. Closest independent specialist-pathology comparable to BakoDx.
- StrataDx: Premier dermatopathology and anatomic pathology laboratory that was acquired by Fulgent Genetics together with Bako Diagnostics in March 2026. Directly comparable in scale, specialty focus, and go-to-market model — BakoDx's sister specialty lab inside the Fulgent portfolio.
- Inform Diagnostics (formerly AmeriPath / Quest Dermatopathology): Specialized dermatopathology and anatomic pathology laboratory with national reach serving dermatologists and podiatrists. Directly competitive with BakoDx in the dermatopathology/lower-extremity pathology niche.
Emerging players
- Castle Biosciences: Molecular diagnostics company focused on dermatologic and ophthalmic conditions (e.g., DecisionDx-Melanoma, DecisionDx-SCC). Comparable as a specialty dermatology-focused diagnostics company, though it primarily sells prognostic tests rather than pathology services.
Others
- Myriad Genetics: Molecular diagnostics company with specialty testing focus. Comparable on molecular diagnostic technology platform and payor-contracted revenue model, but operates in different clinical specialties (hereditary cancer, pharmacogenomics).
Broad incumbents
- Quest Diagnostics: Largest US reference laboratory offering anatomic pathology, molecular, and microbiology services across all specialties. Overlaps with BakoDx in dermatopathology and PCR testing but lacks Bako's exclusive podiatry focus.
- Sonic Healthcare USA: Global pathology and reference lab operator (parent of Aurora Diagnostics) with significant US anatomic pathology footprint serving dermatologists and other specialists.
- Laboratory Corporation of America (Labcorp): National reference laboratory providing dermatopathology, molecular diagnostics, and anatomic pathology services. Broad incumbent with overlapping capabilities but no specialist podiatry positioning.
- NeoGenomics Laboratories: Specialty oncology and molecular diagnostics laboratory serving oncologists and other specialists. Comparable as a US specialty reference lab with payor contracts and field sales force, though focused on oncology rather than podiatric pathology.
- ARUP Laboratories: Major academic-affiliated reference laboratory offering anatomic pathology and molecular diagnostics. Comparable on technology breadth and complexity but serves a different specialist mix than BakoDx.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Bako Diagnostics social profiles
Digital presenceBako Diagnostics compliance and trust
Trust signalCompliance2 records
Bako Diagnostics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Bako Diagnostics leadership team
Management profileNumber of profiles
Profiles2 records
Bako Diagnostics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Bako Diagnostics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Bako Diagnostics
What does Bako Diagnostics do?
Bako Diagnostics is a specialty pathology laboratory providing anatomic pathology, molecular PCR testing, microbiology, and Epidermal Nerve Fiber Density (ENFD) analysis for podiatric physicians, dermatologists, and infectious disease specialists. Every test is delivered with the company's proprietary "intelligence reporting" methodology, which attaches structured treatment recommendations to the diagnostic interpretation.
Is Bako Diagnostics a public or private company?
Bako Diagnostics is a private company. It is classified as corporate owned and is currently acquired.
When was Bako Diagnostics founded?
Bako Diagnostics was founded in 2008. It employs 251 to 500 people.
Where is Bako Diagnostics based?
Bako Diagnostics is headquartered in Alpharetta, United States, in the North America region.
How does Bako Diagnostics make money?
One revenue line is on record: laboratory Testing Services.
Who are Bako Diagnostics's main competitors?
Direct peers on record are PathGroup, StrataDx and Inform Diagnostics (formerly AmeriPath / Quest Dermatopathology). Castle Biosciences is listed as an emerging player. Myriad Genetics is listed as an others. Broad incumbents are Quest Diagnostics, Sonic Healthcare USA, Laboratory Corporation of America (Labcorp), NeoGenomics Laboratories and ARUP Laboratories.
Does Bako Diagnostics have an API?
No public API is recorded for Bako Diagnostics.
What industry is Bako Diagnostics in?
Bako Diagnostics's product category is Diagnostic Pathology Services. Its primary akta.pro industry code is HLAFAMAA, Anatomic Pathology (Histopathology & Cytopathology), with a secondary code of HLAKACAC, Dermatopathology. Its NAICS code is 621511 and its SIC code is 8071.